TODAY -

A vaccine for COVID-19: So near and yet so far

Shobha Shukla *

 A vaccine for COVID-19: So near and yet so far



With the numbers of those infected with COVID-19 (SARS-CoV-2) escalating everyday globally we are indeed wading through turbulent waters with no end at sight. Scientists around the world are literally burning the midnight oil, searching frantically for a treatment to rid the world of this pandemic. It is a race between humans and the virus.

And although it is too early to predict anything, their efforts for developing a vaccine have met with some initial successes, with 5 candidate vaccines having entered phase-3 of their clinical trials. And as we wait with bated breath for the magic vaccine, a historic moment has already set in with the large scale manufacturing of some of these vaccines already begun, including in India.

saving human lives has primacy over money

This is an unprecedented move - to start producing large quantities of vaccines irrespective of the final outcome of the trials. It is a calculated risk that philanthropic organisations and some governments are ready to take by giving precedence to saving human lives over losing money (in case the vaccine does not make it to the final milestone). It will ensure timely and large-scale availability of doses in case that particular vaccine is successful.

AZD1222

One such candidate vaccine is AZD1222 that is being developed jointly by the University of Oxford and AstraZeneca. The Pune-based Serum Institute of India, the largest vaccine manufacturer in the world, that has entered into a manufacturing partnership with AstraZeneca, has committed to manufacture 1 billion (100 crore) doses of this vaccine and has already commenced production.

"This is a big, yet deliverable, assurance for global health as India is already the biggest manufacturer and supplier of more than 60% different kinds of vaccines worldwide. It is vital to ensure that manufacturing of COVID-19 vaccine remains in countries like India so that the world can have access to cheap and affordable prevention against the dreaded virus, without delay by ensuring equitable distribution", said Dr Ishwar Gilada, senior infectious diseases expert, and Secretary General of Organized Medicine Academic Guild (OMAG). Dr Gilada is also the President of AIDS Society of India, and on the governing council of International AIDS Society (IAS).

India is also likely to participate in phase-3 clinical trial of AZD1222. As per a news report, Serum Institute of India said it will apply for a licence from the Indian regulator to start clinical trials of the vaccine in the country very soon.

Dr S Natarajan, President of Organised Medicine Academic Guild (OMAG) and a Padmashree awardee (among the highest civilian honours in the country) hoped that the Indian Government will play a proactive role and expedite clearance to conduct these trials in India. While cautioning that "the results of phase-3 clinical trial will be very important to decide the safety, effectiveness and roll-out of the vaccine for public health use", he conceded that the initial results of this study give hope and that India should be proud to be a part of this initiative.

The results of the Phase-1/2 trial of AZD1222 published in The Lancet, indicate no early safety concerns and no serious side effects by the vaccine in 1077 trial participants aged 18-55 years. The vaccine produced a dual immune response that lasted till at least 56 days after they were immunised. Not only did it produce antibodies, which are the immune system's natural response, but it also produced T-cells that directly kill virus infected cells and are said to last much longer in the human body as compared to the protective antibodies.

Large scale Phase-3 clinical trials are currently underway in the UK (8000 participants) and Brazil (5000 participants) and are due to start in USA (30,000 participants), South Africa (2000 participants) as well as in India (10,000 participants).

4 more vaccines entering phase-3: WHO

As per WHO, apart from AZD1222, their are 4 other vaccines (out of the 24 candidate vaccines currently in clinical evaluation stages) that have entered phase-3 clinical trials, after successfully completing phases-1 and 2 (phases 1 and 2 evaluate safety, immunogenicity and efficacy of the vaccine in a small number of trial participants while in phase-3 the safety, immunogenicity and effectiveness of the potential vaccine is tested in a broader population - often multicountry - over a longer period of time).

Three of these are by Chinese companies, and one is being developed by an American firm Moderna Inc in collaboration with the US government's National Institute of Allergy and Infectious Diseases (NIAID), part of National Institutes of Health (NIH).

US-based biotechnology company Moderna, supported by the National Institute of Allergy and Infectious Diseases (NIAID) is developing a potential coronavirus vaccine candidate mRNA-1273. In fact, Moderna was the first organization to start human trials of mRNA-1273 on March 16, 2020 - 5 days after WHO had termed COVID-19 as a pandemic. The initial phase-1/2 trial has shown promising results. Phase-3 trials are planned to begin this month (in July) on 30,000 participants in USA.

China's state-run Sinopharm Group Co is working on two COVID-19 vaccines being developed by its subsidiary China National Biotec Group Co. (CNBG). As reported by Bloomberg News, these two experimental vaccines are already being offered to employees of large state-owned companies who intend to travel overseas for work. Administering an investigational vaccine (that is still being evaluated in clinical trials) to people outside of the clinical trial protocol is unusual indeed. China National Biotec Group Co. (CNBG) is aiming to produce 200 million doses of inactivated COVID-19 vaccines a year.

China's Beijing-based Sinovac Biotech has also announced positive results from its Phase-1/2 clinical trials of its vaccine CoronaVac and will start phase-3 trials on 9,000 healthcare professionals working in COVID-19 specialised facilities in Brazil and on 4,200 healthcare workers of 7 COVID-19 dedicated hospitals in Bangladesh.

An ideal vaccine against SARS-CoV-2 (Severe Acute Respiratory Syndrome CoronaVirus-2) should be safe and effective after one or two vaccinations; provide protection for a minimum of 6 months and protect old and young alike, including immunocompromised individuals and those with co-morbidities.

Agrees Dr Ishwar Gilada that while phase-3 clinical trials move ahead for these and other vaccines in the pipeline, it is the duty of all the governments, including the Indian government, to be geared to ensure that scientific breakthroughs translate into public health gains without any unnecessary delays. Whenever a safe and effective vaccine for COVID-19 becomes available for public health use, we must have strong health systems and other regulatory mechanisms already in place to be able to deliver it to those most in need of it globally.

Never before the world has conducted a vaccine research so quickly without compromising safety or scientific integrity. It is important to know if a vaccine is safe, immunogenic and effective in protecting us against coronavirus - and - it is equally important to ensure that everyone of us, especially those more vulnerable, to get it as soon as possible.

Dr Anthony S Fauci, Director of National Institute of Allergy and Infectious Diseases (NIAID) had said: "What happens is that in the standard way of developing a vaccine, you don't jump to invest in the next step until you're pretty sure that the step you're in is working... Given the fact that we needed to do this as quickly as possible without sacrificing safety or scientific integrity, the federal government partnered with multiple of these companies and said, we're going to move fast and we're going to assume we're going to be successful. And if we are, we've saved several months. And if we're not, the only thing we've lost is money. But better lose money than lose lives by delaying the vaccine."


* Shobha Shukla wrote this article for e-pao.net
The writer is the founding Managing Editor of CNS (Citizen News Service) and is a noted gender justice advocate.
She is a former senior faculty of Loreto Convent College and current Coordinator of Asia Pacific Media Network to end TB & tobacco and prevent NCDs.
Follow her on Twitter @shobha1shukla)
This article was webcasted on July 25 2020 .



* Comments posted by users in this discussion thread and other parts of this site are opinions of the individuals posting them (whose user ID is displayed alongside) and not the views of e-pao.net. We strongly recommend that users exercise responsibility, sensitivity and caution over language while writing your opinions which will be seen and read by other users. Please read a complete Guideline on using comments on this website.




LATEST IN E-PAO.NET
  • Colonial Knowledge Production in NE #8
  • Violence in Manipur 2023-2025 : Timeline
  • The fight for survival in Manipur
  • A call for unity from displaced voices
  • COVID-19: Update 08 July 2025 : Manipur
  • Dogs Are Staying on the Ground :: Poem
  • Football Tournament at Heinoukhongnembi
  • Condemns Kuki Inpi's Directive
  • Installation Ceremony of Lions Club, Imphal
  • All that can go wrong has gone wrong
  • Manipur peaceful from Delhi's perspective
  • Bashanta Ras @Govindaji #2 : Gallery
  • Hypocrisy & the betrayal of sovereignty
  • Healing with Art for children concluded
  • Manipur : Champions 24th Junior Natl Wushu
  • Path to Becoming a Leader Who Inspires
  • Van Mahotsav 2025, festival of life
  • The Flavours of Life :: Poem
  • Assault on sensibilities of the media
  • Revival of MPP after years of bitter disputes
  • Ougri Lirol :: Part 2 : Ooba Video
  • Jianreilung, Chingamba, Masounii : eMing
  • How Jessami conservation of Nongin
  • Shija Hospitals turns 40
  • COVID-19: Update 06 July 2025 : Manipur
  • The Indomitable Young Souls :: Poem
  • Growing network of drug dealers in country
  • Politics of SoO pact since 2008
  • No takers for disturbance-free education
  • 31st Governor Cup Polo Tournament : Gallery
  • PM welcome to Manipur: Feel the reality
  • Kainkhol wins best Social Message Film Award
  • Distortion of facts: Manipur sports movement
  • Govt services reach Manipur's tribal villages
  • 134th Durand Cup Trophies Flag Off
  • COVID-19: Update 05 July 2025 : Manipur
  • How to take care of oily skin in monsoon
  • First-Ever Tripura Esports Championship
  • Konung Kang Chingba #1 : Gallery
  • Manipur Iskcon's 25th Ratha Yatra 2025
  • Native Threshing machine made for farmers
  • COVID-19: Update 04 July 2025 : Manipur
  • Riso Ejang: Youth-led Transformation
  • Include males too in addressing HPV
  • Whispers from the past :: Poem
  • LPU opens permanent outreach centre
  • Raj Bhavan moving on the right track
  • Speculations over PM Modi's visit to state
  • Colonial Knowledge Production in NE #7
  • Make Yourself Visible to Opportunity
  • Orange bowl: tradition with ecological wisdom
  • 10 ways to keep a kitchen garden disease free
  • Between PR, military mandates & AFSPA
  • Allocation fund for MLALAD Fund during PR
  • Denounces Killing of KNA Deputy C-in-C
  • COVID-19: Update 03 July 2025 : Manipur
  • Cases of fake Aadhaar cards
  • Sincere dealing must for stricter Aadhaar
  • Archaeology: Culture of Manipur : Booklet
  • Wanna be a singer? Get Botox
  • A Central institute in Manipur
  • Nagging in the name of love
  • COVID-19: Update 02 July 2025 : Manipur
  • 'Benefits' of Indira's Emergency
  • Social Stigma :: Poem
  • Inking a peace pact: Why, how: SoO quagmire
  • Van Mahotsav under shadow of declining forest
  • 11th Th Kishan Memorial Lecture : Gallery
  • Manipur crisis & the Left media's blind spot
  • COVID-19: Update 01 July 2025 : Manipur
  • Bombom RK : Musclemania Universe NYC
  • The Grief :: Poem
  • Music Concert & Quiz (MCQ) 2.0
  • SoO agreement unlikely to be scrapped
  • Regulating use of plastic carry bags
  • Mera Houchongba @Kangla #4 : Gallery
  • International Day of Yoga @JNMDA : Gallery
  • BD Behring: The inimitable Gentleman I knew
  • Violence in the name of patriotism : Misguided
  • Daily oral vs long-acting injectable for HIV
  • COVID-19: Update 30 June 2025 : Manipur
  • Smile :: Poem
  • Why was President's Rule imposed ?
  • BJP under pressure to forge unity
  • Kang @Leikai in Imphal : Gallery
  • July Calendar for Year 2025 : Tools
  • COVID-19 : A recurring crisis in Manipur
  • DC Kaith and Forestry in Manipur : Book
  • COVID-19: Update 29 June 2025 : Manipur
  • Longing for Peace :: Poem
  • Black badge, slogan protest by peeved scribes
  • Present the true picture before Delhi
  • Pung-Cholom @ Polo Tournament : Gallery
  • Life: A Journey Through Thought & Being
  • Khongjai Hills & Kuki claim to indigeneity
  • Master Time by Managing Information
  • COVID-19: Update 28 June 2025 : Manipur
  • Pride & patriotism in CCpur's army families
  • The Power of Poppy - 87 :: Poem
  • World Decarbonisation Day: green environment
  • Welcome Home - Nganthoi #2 : Gallery
  • Loss of two precious lives from Manipur
  • Balancing civil liberties with public safety
  • COVID-19: Update 27 June 2025 : Manipur
  • Gender equality & human rights are indivisible
  • Stay hydrated this summer season
  • Silent Half of the Sun :: Poem
  • Connecting the dots in the wishlist
  • Assembly record tampering claims by ex-CM
  • The immortal legacy of Pukhramba Kajao
  • International Day against Drug Abuse 2025
  • COVID-19: Update 26 June 2025 : Manipur
  • Black pottery from Ukhrul - tribal heritage
  • Program on "Mission-Drug Free Campus"
  • Play makes a better world
  • Urgent Appeal to the Honourable MLAs
  • Tribal Empowerment Campaign at CCpur
  • Talk doing the round: PM to come
  • 'Emergency' relief for under-fire BJP
  • Golden Jubilee Art Fair @Imphal : Gallery
  • Declaration: Meetei People Convention, Delhi
  • A Flower Among the Rocks :: Review
  • Book Donation Campaign
  • Improved road connectivity boosts livelihoods
  • To Have Great Dreams :: Poem
  • COVID-19: Update 25 June 2025 : Manipur
  • Regret vs Sorry: Technical & moral insight
  • Cocktail of inept Govt, selfish people
  • State trailing others in cleanliness
  • Colonial Knowledge in NE India #6
  • UHI effect & rising temperatures in Manipur
  • Frequent road blockades cripple economy
  • COVID-19: Update 24 June 2025 : Manipur
  • Unite Health with Community health services
  • NSU, Imphal, tops IIRF Ranking 2025
  • Endless conflict :: Poem
  • Pak nobel pish prize for Trump
  • May 3, 2023 - June 24, 2025: Failure of Delhi
  • Hotter days, sudden rainfall no more a rarity
  • "The Great June Uprising" #2 : Gallery
  • How to Build a Career, Lead with Purpose
  • 2nd Foundation Day- Karnataka Meitei Assn
  • COVID-19: Update 23 June 2025 : Manipur
  • NSCN-IM Amnesty threatens to isolate it
  • Sunset :: Poem
  • Intl Yoga Day for a healthier environment
  • Of clogged drains and plastics
  • Poor roads testify Govt indifference
  • Welcome Home - Nganthoi #1 : Gallery
  • The Silent Erosion of Manipuri Language
  • Design health services around people
  • Serene Hills Host Inspiring Int'l Yoga Day
  • COVID-19: Update 22 June 2025 : Manipur
  • Chopper services between Senapati & Imphal
  • High Court Judges interacted with convicts
  • Redyeing the Fabric :: Poem
  • Differences yet to be resolved stand
  • Border fencing rage as solution eludes
  • Radio E-pao: 14 new songs updated
  • Climate Adaptive Agroforestry
  • Manipur overlooked demographic shifts
  • Young designers shine on Fashion Stage
  • COVID-19: Update 21 June 2025 : Manipur
  • International Day of Yoga at Lamphelpat
  • International Day of Yoga at JNMDA
  • The Power of Poppy - 86 :: Poem
  • Keishampat Lairembi Haraoba #1 : Gallery
  • Crisis in Manipur's Contemporary Education
  • Best 8 Performances in Manipuri Cinema
  • Identity: Caught between China & India ?
  • COVID-19: Update 20 June 2025 : Manipur
  • To The Father Who Listens :: Poem
  • How does net suspension affect youths ?
  • Targeting farmers to cripple state's economy
  • The virus is back and spreading
  • Who is afraid of Manipur ?
  • A threatened lily growing at Shirui Hills
  • World Environment Day in Manipur : Gallery
  • Ambubachi Mela at Maa Kamakhya
  • COVID-19: Update 19 June 2025 : Manipur
  • Dolls made from repurposed vegetable refuse
  • Condemns Attack on Farmer & Killing
  • Abhorrent politics of SoO
  • Police arrogance on harmless drivers
  • "The Great June Uprising" #1 : Gallery
  • UK Meetei diaspora run for Myanmar : Gallery
  • Thang-Ta Day @Khuman Lampak #3 : Gallery
  • 50 years of Pebet #2 : Gallery
  • Indo-Naga Talks (From 2012) :: Timeline
  • Protest @Checkon -AT arrest [Jun 9] : Gallery
  • Protests - AT arrest [Jun 8 night] : Gallery
  • Aftermath of flooding @ Khurai #1 : Gallery
  • /li>
  • Flooding at JNIMS Hospital #2 : Gallery
  • North East NSS Festival @ MU : Gallery
  • Trump's tariff legacy & its global echo
  • Flooding Imphal East [31 May] #3 : Gallery
  • Flooding Imphal East [31 May] #2 : Gallery
  • Flooding Imphal East [31 May] #1 : Gallery
  • S Nirupama @Miss Universe : Gallery
  • Protesters to Raj Bhavan [May 25]: Gallery
  • Human Chain @Airport road [May 26]: Gallery
  • Miss Shirui Pageant Contestant: Gallery
  • 48 hrs Bandh: protest security forces: Gallery
  • Protest Rally: Journalist harassment: Gallery
  • HSLC 2025: Full Result (Check Roll No)
  • HSLC 2025: Important Info & Grading System
  • HSLC 2025 : Compartmental candidates
  • HSLC 2025 : Comparative Statement
  • HSLC 2025 : Statistical Abstract
  • HSLC 2025 : District Pass Percentage
  • HSLC 2025 : Govt School Pass %
  • HSLC 2025 : Aided School Pass %
  • HSLC 2025 : Private School Pass %
  • People's Convention on 3rd May #2 : Gallery
  • Featured Front Page Photo 2025 #2: Gallery
  • Riya Khwairakpam : HSE Science Topper
  • Keisham Hannah : HSE Arts Topper
  • Warepam Lidia : HSE Commerce Topper
  • HSE 2025 Result : Science Full Result
  • HSE 2025 Result : Arts Full Result
  • HSE 2025 Result : Commerce Full Result
  • HSE 2025 Information / Abbreviation
  • HSE 2025 Topper : Science
  • HSE 2025 Topper : Arts
  • HSE 2025 Topper : Commerce
  • HSE 2025 : Pass Percentage
  • HSE 2025 : Result Abstract
  • HSE 2025 : Candidates with Highest Marks
  • President's Rule in Manipur : 1967 - 2025
  • Downloadable Manipuri Calendar :: 2025